We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
£124.31
Springer Antimicrobial Resistance in the 21st Century (Emerging Infectious Diseases of the 21st Century)
Price data last checked 47 day(s) ago - refreshing...
Price History & Forecast
Last 44 days • 44 data points (No recent data available)
Price Distribution
Price distribution over 44 days • 2 price levels
Current Price
Price Analysis
Most common price: £124 (22 days, 50.0%)
Price range: £124 - £132
Price levels: 2 different prices over 44 days
Description
Product Description This comprehensive, up-to-date volume defines the issues and offers potential solutions to the challenges of antimicrobial resistance. The chapter authors are leading international experts on antimicrobial resistance among a variety of bacteria, viruses including HIV and herpes, parasites and fungi. The chapters explore the molecular mechanisms of drug resistance, the immunology and epidemiology of resistance strains, clinical implications and implications on research and lack thereof, and prevention and future directions. Review “Each chapter is considered a scientific review article and is well written and well referenced. … This book has been written for both students and clinicians. However, graduate students in microbiology would be a more appropriate audience than professional students.” (Christopher J Destache, Doody's Book Reviews, May 17, 2019) From the Back Cover Antimicrobial resistance is now a general problem. Many of us have elderly relatives who died from a drug-resistant infection, and some of us have suffered from a resistant urinary infection that likely came from intestinal bacteria following antibiotic consumption. Antimicrobial Resistance in the 21st Century provides a broad introduction to the subject in which the situation with problematic pathogens is detailed, the biology of resistance is described, and gaining approval for new antibiotics is discussed. Some topics are immediately practical, such as watching for resistant pathogen sub-populations in cultures taken from patients; other topics point to future research efforts that may lead to new antimicrobials and ways to stimulate the action of existing ones. Overall, Antimicrobial Resistance in the 21st Century provides an update for physicians, serves as a starting point for graduate students interested in solving the resistance problem, and may serve as a text for a course on resistance. Lay readers familiar with microbiology will gain an appreciation for a medical issue that promises to be one of the most important of our time. Ignatius Fong, Department of Medicine, University of Toronto Series Editor – Emerging Infectious Diseases of the 21st Century David Shlaes, Founder, Anti-Infectives Consulting Editor – Antimicrobial Agents and Chemotherapy Karl Drlica, The Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey About the Author Ignatius Fong is the Editor of Springer’s Emerging Infectious Diseases of the 21st Century series. He was the Chief Editor for six books and the sole author for another six books published in the series. He completed his residency training in Internal Medicine at the University of Toronto and as a Fellow in Infectious Diseases at the University of Washington, Seattle. Dr. Fong has published studies concerning a variety of infectious diseases that include therapeutics and pharmacology of antibiotics, AIDS and the treatment of opportunistic infections, mechanistic and treatment studies of mucosal candidiasis, and pathogenic studies on infection and induction of atherosclerosis in animal models. He was Chief of Infectious Diseases at St. Michael’s Hospital (Toronto) for 34 years; he is still on staff in Infectious Diseases and is a Professor of Medicine, Department of Medicine at the University of Toronto, Canada. Dr. David Shlaes, author of Antibiotics, The Perfect Storm (Springer) and The Drug Makers (Lulu), has had a thirty-year career in anti-infectives spanning academia and industry with a long-standing scientific interest in antimicrobial resistance. He trained in infectious diseases at Case Western Reserve University in Cleveland. He then joined the faculty and ultimately became a Professor of Medicine there. Dr. Shlaes left academia to become Vice President for Infectious Diseases at Wyeth Pharmaceuticals in 1996, where he was an important leader in the development of tigecycline. In 1998, he
Product Specifications
- Brand
- Springer
- Format
- hardcover
- ASIN
- 3319785370
- Domain
- Amazon UK
- Release Date
- 19 November 2018
- Listed Since
- 22 February 2018
Barcode
No barcode data available